Nicole Epard
Acute Care · Huber Heights, OHNPI 1619534781
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 548 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 548 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Grifols USA, LLC$642
- Actelion Pharmaceuticals US, Inc.$590
- Sanofi$590
- plus $4K from 27 others
What the payments were for
- Food & beverage$9,66097%
- Education$2843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,771 |
| GSK | 134 | $1,701 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,045 |
| Grifols USA, LLC | 37 | $642 |
| Actelion Pharmaceuticals US, Inc. | 32 | $590 |
| Sanofi | 33 | $590 |
| Axsome Therapeutics, Inc. | 48 | $514 |
| Boehringer Ingelheim | 27 | $420 |
| Inspire Medical Systems, Inc. | 8 | $346 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $255 |
| United Therapeutics Corporation | 9 | $210 |
| Merck | 9 | $200 |
| Amgen | 13 | $181 |
| Bayer | 9 | $176 |
| Baxter Healthcare | 8 | $164 |
| Mylan Specialty L.p. | 10 | $153 |
| Philips North America LLC | 7 | $150 |
| Lilly USA, LLC | 2 | $110 |
| Jazz Pharmaceuticals Inc. | 6 | $109 |
| Gilead | 4 | $84 |
| Shionogi Inc | 3 | $71 |
| Paratek Pharmaceuticals, Inc. | 4 | $71 |
| Pulmonx Corporation | 3 | $70 |
| Insmed, Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Genentech USA, Inc. | 2 | $44 |
| Verona Pharma, Inc. | 2 | $39 |
| Viatris Specialty LLC | 2 | $38 |
| Kaleo, Inc. | 2 | $26 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Electromed, Inc. | 1 | $18 |
| Covis Pharma GmbH | 1 | $17 |
| Inogen, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,944 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 399 | $413,516 |
| Dupixent PenDupilumab | 20 | $82,636 |
| TezspireTezepelumab-Ekko | 15 | $67,464 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $59,962 |
| Spiriva RespimatTiotropium Bromide | 38 | $26,894 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $21,120 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $18,640 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $18,210 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 275 | $7,089 |
| Roflumilast | 68 | $5,675 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,580 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $3,467 |
| Azithromycin | 197 | $3,397 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,787 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $2,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,701 | $452,846455 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,771 | $133,00582 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $420 | $45,53453 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Huber Heights
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Ileah ReichertColumbus$73K
- Davida PraterBeavercreek$46K
- Dawn FrenchAlliance$40K
- Holly McKibbenColumbus$23K
- Jody HussBlue Ash$13K
- Julie LurieCincinnati$13K
- Susan BrooksMount Vernon$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.